Noninvasive imaging for diagnosing gastric and pancreatic cancer
Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer
This study is testing two new imaging agents to see if they can help doctors diagnose gastric and pancreatic cancers more accurately without needing invasive procedures.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Huashan Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06203613 on ClinicalTrials.gov |
What this trial studies
This study investigates the diagnostic efficacy and safety of two imaging agents, [18F]F-H3RESCA-3A12 and [68Ga]Ga-NOTA-3A12, for the noninvasive diagnosis of metastatic gastric and pancreatic cancers. It aims to evaluate the sensitivity and specificity of these agents in providing clear imaging for clinical diagnosis and treatment decisions. By utilizing advanced PET/CT technology, the study seeks to establish a new method for target-specific diagnosis of these cancers.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 with confirmed gastric or pancreatic cancer.
Not a fit: Patients with severe hepatic or renal insufficiency or those who have undergone targeted therapy before the imaging procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and noninvasive diagnostic methods for gastric and pancreatic cancer, improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using advanced imaging techniques for cancer diagnosis, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) Age between 18 and 65 years old, gender is not limited. (2) Patients with gastric or pancreatic cancer confirmed by puncture or surgical pathology. (3) Written informed consent signed by the subject or his/her legal guardian or caregiver. (4) Willingness and ability to cooperate with all programs of this study. Exclusion Criteria: - (1) Severe hepatic or renal insufficiency; (2) Targeted therapy before radiotherapy or PET/CT scan. (3)Renal function: serum creatinine less than or equal to the upper limit of the normal range;Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range. (4) History of serious surgery in the last month. (5) Those who have participated in other clinical trials during the same period.
Where this trial is running
Shanghai
- PET Center, Huashan Hospital, Fudan University — Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Fang Xie, PhD — Huashan Hospital
- Study coordinator: Yihui Guan, MD
- Email: guanyihui@hotmail.com
- Phone: 13764308300
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.